Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule
Stevenage, UK, 5 September 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces its conference attendance programme for the remainder of 2024.
Forthcoming events include:
• ISCT Europe Regional Meeting, 4 – 6 September in Gothenburg - speaking
• Healthtech Innovation Day, 17 – 18 September in Paris - speaking, investor meetings
• Sachs Biotech in Europe Forum,…
NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Stevenage, UK, 5 August 2024 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation.
It is one of five recipients of the 2024 In Vivo Target Validation grants in collaboration with Biospective. The funding will be used to support its discovery programme for a treatment for Amyotrophic Lateral Sclerosis (ALS) (also known as…
Read eNews for September here
Featuring:
✅ Tony Jones, CEO, One Nucleus monthly news
✅ Are You Targeting Your Advertising Spend for the Best Return? by Alicia Gailliez
✅ Has Biotech Investment Turned a Corner? - BioIndustry Association (BIA)
✅ What’s Hot in the Diagnostic Deal Space? - PharmaVentures
✅ What were the top 10 locations for UK Life Science investment in the UK in 1H 2024? - Pioneer Group
✅ The Role of Innovative R&D and GenAI in Helping to Tackle AMR - Deloitte
✅ Don't Miss Your Opportunities at BIO-Europe - Deadlines Approaching! -EBD Group
Sponsored by…
Merck’s EMEA Advance Biotech Grant Program
Merck’s EMEA Advance Biotech Grant Program https://informaconnect.com/bioeurope/merck-advance-biotech-grant/ is designed to support emerging biotech companies on the forefront of innovative drug development. Targeted at biotechs with a focus on novel modalities and therapeutics, this program aids companies with at least one biologic in the pipeline, particularly those working on mAbs, ADCs, mRNA, gene therapy, cell therapy, and vaccines.
The program offers significant prizes: the winner receives €148,400 in bioprocessing technologies, consultation…
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Company Secures Additional Financing to Advance Clinical Programmes in Immuno-Oncology and Inflammatory Bowel Disease Through to Data Readout
Cambridge, UK – 27 August 2024: Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce that it has received regulatory approvals to initiate clinical studies for its first two programmes in advanced melanoma (MELODY-1…
The August edition of our People Pathways newsletter is out now! Read the newsletter here.You can read about:✅ One Nucleus upcoming courses - don't forget, as a One Nucleus member, you can access discounts up to 30%;✅ Our upcoming BLSA SIG webinar on the Green Business Impact Programme jointly delivered by Allia and PECT;✅ EBD Academy courses - member savings available;and more...
WEST CHESTER, Pa. and CAMBRIDGE, England – Wednesday, August 21, 2024 – Supreme Group today announced the acquisition of BioStrata, an award-winning agency offering comprehensive marketing communication services to the life science sector. Based in Cambridge, UK, and servicing clients globally, BioStrata has helped more than 200 life science organizations achieve their business goals across life science research tools, medical devices, diagnostics, contract research and manufacturing, biopharma, and other areas.
This strategic addition, backed by growth-oriented private equity firm…
The MycoScope™ Mycoplasma PCR detection kit from AMSBIO uses polymerase chain reaction (PCR) technology to detect mycoplasma infections in less than 3 hours. Offering high-sensitivity detection, rapid results, and compatibility with existing PCR setups, this kit reduces the risk of contamination spread saving valuable time and resources.
As reported in the ISSCR standards report (2023) a sizeable proportion of cell cultures (up to >80%) are infected with mycoplasma. While contaminating mycoplasma may grow slowly without killing the cells, the infection affects…
The biopharma industry veteran, founder of Medivation, and serial entrepreneur joins T-Therapeutics to support the development of the biotechnology company’s pipeline of next-generation soluble TCR therapeutics targeting cancer and autoimmune indications.
Dr. Hung is a successful serial entrepreneur in the oncology space. He founded Medivation in 2003 which was sold to Pfizer for $14.3 billion in 2016. At Medivation, Dr. Hung identified, in-licensed, and led bench-to-bedside development of enzalutamide (XTANDI®) for advanced prostate cancer, taking it from first in vitro laboratory experiment…
Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed Carlos Garcia-Echeverria, Katharina Kreymborg and Karen Lackey as the first members of its Therapeutic Innovation board to steer its drug discovery strategy.
Therapeutic Innovation is Cancer Research Horizons’ drug discovery division. From target identification to candidate drug nomination, Therapeutic Innovation’s scientists collaborate with academic and industrial partners to progress promising ideas, de-risk assets and bring projects to their next value inflection point.
The new board members’ experience…